A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer patients.

Pierre Heudel,Antoine Arnaud,Jean-Sébastien Frenel,Sylvie Chabaud,Benoit You,Laetitia Stefani,Claire Garnier-Tixidre,H. Simon,Dominique Beal Ardisson,Jean Philippe Jacquin,Francesco Del Piano,Alain Lortholary,Claudiu Cornea,Tifenn Lharidon,Rémy Largillier,Fabien Brocard,Eric Legouffe,Mustapha Atlassi,Anne Claire Hardy-Bessard,Thomas Bachelot

A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer patients.

2019

1043Background: For ER+/HER2- metastatic breast cancer (mBC), efficacy of endocrine therapy + chemotherapy combination remain an open question. We hypothesized that continuing ER targeted therapy a...

Keywords:

Targeted therapy
Vinorelbine
Aromatase inhibitor
Endocrine system
Pathology
Oncology
Internal medicine
Chemotherapy
Metastatic breast cancer
Medicine
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations